Edition:
United Kingdom

People: TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

5.37USD
19 Oct 2018
Change (% chg)

$-0.21 (-3.76%)
Prev Close
$5.58
Open
$5.60
Day's High
$5.67
Day's Low
$5.26
Volume
393,358
Avg. Vol
349,157
52-wk High
$17.30
52-wk Low
$4.95

Charney, Laurence 

Mr. Laurence Neil Charney is an Independent Director of TG Therapeutics, Inc., since March 2012. Since 2007, Mr. Charney has served as a business strategist and financial advisor to Boards, CEOs and investors. Previously, from 1970 through June 2007, Mr. Charney was a senior audit partner at Ernst & Young, LLP, a registered public accounting firm, retiring as a practice leader in the Americas Quality and Risk Management Group. Mr. Charney currently serves as an executive responsible for quality and professional leadership development for Frankel, Loughran, Starr & Vallone, LLP, CPA's and as a director and audit committee chairman of Pacific Drilling S.A. and Kenon Holdings LTD, both NYSE listed companies. In addition, Mr. Charney previously served as a director and audit committee member of Marvel Entertainment, Inc., Mrs. Fields Original Cookies, XTL Biopharmaceuticals, Ltd., Pure Biofuels, Inc., and Iconix Brand Group, Inc. In addition to his extensive experience on the boards of various corporate entities, Mr. Charney is also active on the boards of several non-profit organizations. Mr. Charney graduated with a B.B.A. degree from Hofstra University and completed the Executive MBA in Business program at Columbia University.

Basic Compensation

Total Annual Compensation, USD 70,824
Restricted Stock Award, USD 166,500
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 237,324

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Weiss

9,926,620

Sean Power

1,009,840

Adam Waldman

--

Laurence Charney

237,324

Yann Echelard

221,912

Kenneth Hoberman

227,324
As Of  31 Dec 2017